Actuate Therapeutics (ACTU)
Develops elraglusib, a GSK-3β inhibitor, for metastatic pancreatic cancer.
$1.50
Pre-market+0.20 (+14.94%)
At close$1.31(−15.26%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.18
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.33−$0.32−$0.30−$0.25−$0.18−$0.24−$0.20Pending
Estimate−$0.29−$0.30−$0.19−$0.27−$0.24−$0.23−$0.21−$0.18
Surprise−13.8%−6.7%−57.9%+7.4%+25.0%−4.3%+4.8%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.18 | — | — |
| Aug 2026 | −$0.21 | −$0.20 | +4.8% |
| May 2026 | −$0.23 | −$0.24 | −4.3% |
| Mar 2026 | −$0.24 | −$0.18 | +25.0% |
| Nov 2025 | −$0.27 | −$0.25 | +7.4% |
The latest year is open to everyone — the 10 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Sep 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.18 | — | — | — | — | — | — |
| Aug 14, 2026 | −$0.21 | −$0.20 | +4.8% | — | — | — | +3.6% |
| May 14, 2026 | −$0.23 | −$0.24 | −4.3% | — | — | — | −9.7% |
| Mar 26, 2026 | −$0.24 | −$0.18 | +25.0% | — | — | — | −5.3% |
| Nov 13, 2025 | −$0.27 | −$0.25 | +7.4% | — | — | — | +0.5% |
The latest year is open to everyone — the 10 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Sep 24, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||